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ABSTRACT 
Introduction: Hyperbaric oxygen therapy (HbOT) as adjunctive therapeutic intervention has been shown 
to improve the rate of wound healing and prevention the risk of amputation. Guidelines for treating 
these infections have been published to help clinicians decide the best approach. The aims of the present 
review is to summerize and critically analyze the findings of research studies that focus on the update of 
hyperbaric oxygen therapy to diabetic foot ulcer  for wound healing, prevention risk to amputation, 
and cost effeciency based on evidence based with the critical appraisal stage. Method: Several online 
bibliographical databases were searched, including Proquest, Ebscho,  MedScape®, PubMed®, in the 
range 2010-2015 and using the keyword  hyperbaric oxigen therapy, wound healing, amputation, 
amputation risk, cost effeciency, diabetic foot ulcer. Result: The searching process left a total of 11 
articles relevant for review. Discussion: HBOT is just effective for special condition, and it can not 
prevent absolutely for amputation, but it is potentially cost effective or even cost saving for DFU. 
 
Key words: hyperbaric oxygen therapy, diabetic foot ulcer, wound healing, prevention risk of 
amputation, cost efficiency 
 
INTRODUCTION 
   Diabetes mellitus (DM) is one of the 
most deceitful diseases that affect more than 
371 million people all over the world in 2015; 
by 2030 this will rise to 552 million (Iversen, 
2015). In addition to the increasing 
prevalence, patients with diabetic are faced 
with numerous complications. Of all diabetic 
complications, diabetic foot ulcer (DFU) is one 
of the most devastating and costly (Lavery, 
2012). Diabetic foot  ulcers (DFU)  are  a  
major health problem and  an important 
risk factor  for morbidity and  mortality 
among people with diabetes mellitus 
(Brownrigg et al., 2012). The annual 
incidence of diabetic foot ulcer is 
approximetely 1-4 %, and lifetime risk 
can range from 15 % to as high as 25 % 
(Bartus & Margolis, 2014). Without early 
treatment, a foot ulcer may aggravate until it 
becomes infected and chronic. Chronic wounds 
are difficult to heal, despite medical and nursing 
care, and may lead to impaired quality of life 
and functioning, amputation, or even death 
(Mayfield, et al., 2014).  
 In addition, adjunctive therapeutic 
interventions such as hyperbaric oxygen 
therapy (HBOT) have been shown to improve 
the rate of wound healing and prevention the 
risk of amputation (Londahl, et al., 2011). 
Many of these patients are referred to 
specialized wound centers, where 
hyperbaric oxygen therapy (HBOT) has  
become a mainstay  in   healing wounds, 
especially diabetic foot  ulcers (Khrisnan 
& Baker, 2010). HBOT has been suggested to 
increase plasma oxygen levels and improve 
wound healing through the inhalation of 100 
percent oxygen at 2.0–2.5 atmospheres 
absolute (ATA) pressure in a compression 
chamber  (Kranke & Banet, 2012). HBOT has 
been in use for more than 50 years, it is thought 
to aid healing by supplying oxygen to the 
wound (Duzgun, et al., 2013). The efficacy of 
treatment with  HBOT (Hyperbaric Oxigen 
Therapy)  in diabetic  foot  ulcer  has been 
evaluated  for more  than  20 years, but  its 
use has never become  routine,  its use is a 
reality that in recent  years is increasingly 
consolidating,  especially as an adjuvant  to 
conventional therapies  and  the  NPWT 
(Negative Pressure  Wound  Therapy) and  
dermal  substitutes (Chen & Juhn, 2010). In 
addition, many studies, including some 
meta-analyzes,  documenting the positive 
role of HBOT in prevention  the risk of  
amputation, although  a recent  meta-
analysis  it is clear  the  short- term  benefit,  
but  for the  long-term studies  would  be 
needed  to  be so designated  such  as to  
minimize  any bias (Luc i ano ,  Fe r r en t i ,  
e t  a l ,  2010) .   
   There is only limited information 
available on the economic aspects of adjunctive 
HBOT for management of DFU. Several cost 
studies have suggested that use of adjunctive 
HBOT could produce cost savings (Anderson, 
et al., 2014). Given the high costs and 
substancial economic  burden incurred with 
diabetic foot  ulcer, optimal strategies for 
prevention and treatment of diabetic foot ulcer  
need to be followed (Zamboni, et al., 2014). 
Guidlines for treating these infections have 
been published to help clinicians decide the best 
approach (Kessler, et al., 2013). Its purpose is 
to critically analyze and evaluations  the 
finndingsof research studies that focus on the 
update of hyperbaric  oxygen therapy  for 
wound healing, prevention amputation risk, 
and cost effeciency based on evidence based 
with the critical appraisal stage. 
 
METHODS 
Starts from a question “Is the hyperbaric  
o x y g e n  therapy  for wound healing, 
prevention amputation risk, and cost 
effeciency”. Key search terms included combi-
nations of words such as hyperbaric oxigen 
therapy, wound healing, amputation, 
amputation risk, cost effeciency, diabetic foot 
ulcer, diabtes melitus. Several online 
bibliographical databases were searched, 
including Proquest, Ebscho, MedScape®, 
PubMed®, A manual search, based on the 
reference list of retrieved articles, was also 
undertaken. Inclusion criteria for the search 
were primary research studies that discussed 
the update hyperbaric  oxygen therapy  for 
wound healing, prevention amputation risk, 
and cost effeciency, written in English, and 
published in peer-reviewed journals between 
2010 and 2015. This helped to ensure that the 
results were of high quality and indicative of 
recent research in this area. The original series 
of searches resulted in a total of 60 articles. The 
citation from each was reviewed, and 30 articles 
were deemed  not relevant, as they did not meet 
the inclusion criteria.  The abstracts of the 
remaining 30 articles were then reviewed, and 
25 were found to be pertinent. Following this, 
the full text of each of the 25 articles was 
retrieved and reviewed. Fourtheen articles were 
excluded, as they did not meet all of the 
inclusion criteria, which left a total of 11 articles 
relevant for review. 
 
RESULT 
Base on 11 article journals reviewed, 5 
journals from USA and others are from Poland, 
Canada, China, Italy, Sweden, and Rhode 
Island, used various methode that are literatur 
review, cohort study, randomize control trial, 
randomize single center double blinded placebo 
controlled clinical trial, systematic review and 
meta-analyses and also observational study. 
Each journal article was read thoroughly, and  
key ideas or codes relevant to the topic were 
highlighted. Finally, setiap each catergory 
filtered and discussed so the content and out 
come of this review can be new reference.  
HBOT and the Fuction 
Precise mechanism of action of HBOT in 
DFU healing has not been uncovered yet. 
Increased oxygen levels in wound environment 
instigate healing by a mechanism of 
angiogenesis. The process involves physical 
dissolution of oxygen in plasma, leading to 
increased supply of oxygen to hypoxia-affected 
tissues. In DFU pathogenesis, local and 
systemic metabolic disorders lead to abnormal 
oxygen supply to affected tissues, affecting 
locally the immunological system and 
favouring wound infection. Reduced activity of 
phagocytic macrophages, reduced chemotaxis, 
and adhesion of neutrophils are observed in 
DFU. Reduced immunity of tissues favours 
development of pathogenic bacterial flora, 
including anaerobic microorganisms. They 
release toxins causing hypoxia and oedema of 
tissues (Heinzelmann, et al., 2002; Mader, et 
al., 1980; Heng, et al., 2000; Thom, et al., 2011 
cited by Waniczek, 2013). 
Hyperbaric chamber has a bactericidal 
and bacteriostatic effect. Oxygen administered 
under increased ambient pressure enhances in 
vitro phagocytosis in regions of limited 
perfusion by increasing local oxygen tension to 
levels consistent with normal phagocytic 
function (Thom, 2011 cited by Waniczek, 
2013). At the pressure of 2.5 ATA and 
respiration with 100% oxygen, its tension in the 
plasma may be as high as 2000mmHg, causing 
a 10–15-fold increase in oxygen transport, a 4-
fold increase in oxygen diffusion to tissues on 
the arterial side, and a double increase on the 
venous side of the capillary circulation (Faglia, 
et al., 1996; Thom, et al., 2011 cited by 
Waniczek, 2013). Oxygen is an important 
cellular signal regulating intracellular and 
intratissue transformations. Increased oxygen 
level in chronically hypoxic or ischaemic 
wounds stimulates proliferation and 
differentiation of epithelial cells and fibroblasts 
and collagen synthesis in fibroblasts. Oxygen is 
a potent proangiogene. The element increases 
neovascularisation by angiogenic stimulation 
leading to newblood vessel formation from 
local endothelial cells and by the stimulation of 
the systemic stem/progenitor cells to 
differentiate in the form of blood vessels 
(Waniczek, 2013). It was demonstrated that 
HBOT stimulates vasculogenic stem cell 
mobilisation from bone marrow and recruits 
them to skin wound (Thom, et al., 2011 cited by 
Waniczek, 2013). Increased tissue oxygenation 
during HBOT improves also tolerance to 
ischemia and reducesmetabolic abnormalities 
in those tissues (Ramon, 1998; Selcuk, 2012 
cited by Waniczek, 2013).  
HBOT and DFU Wound Healing 
HBOT comprises patient inhalation with 
pure oxygen at the pressure of 2-3 absolute 
atmospheres ATAs (1 ATA= 14.7 psi, 1 kg per 
square centimeter, 101.3 kPa, 760 torr, or 
760mmHg) provided by appropriate single- and 
multipatient pressure chambers. A single 
session lasts for 70–120 minutes, usually 90 
minutes, and the number of sessions usually 
exceeds 20. HBOT-related complications are 
rare and involve claustrophobia, ear, sinus, or 
lung damage due to the pressure, temporary 
worsening of short sightedness, and oxygen 
poisoning (Thom, et al., 2011 cited by 
Waniczek, 2013). Besides the commonly 
known relative and absolute contraindications, 
transcutaneous oximetry (TcPO2) is considered 
an additional criterion of classification for 
HBOT, treated as a valuable prognostic factor 
for ulceration treated with themethod 
(Feldmeler & Hampson, 2002  cited by 
Waniczek, 2013). In DFU patients, the TcPO2 
method-measured oxygen pressure over 
400mmHg at 2.5 ATA or over 50mmHg in pure 
oxygen environment at normal atmospheric 
pressure should be perceived as a good 
prognostic index (Waniczek, 2013). 
Many studies shown influence HBOT to 
DFU wound healing (Table 1). Rielli, et al 
(2013), melakukan systematic review dan 
metaanalisis beberapa jurnal yang sesuai 
dengan kriteria inklusi mereka yaitu 
randomized controlled clinical trial or 
comparative observational study comparing 
systemic HBOT as the intervention to standard 
wound care (i.e., debridement, dressings, 
antibiotics, and minimization of pressure on the 
wound) or sham therapy; human participants 
(age ≥ 18 years old) suffering from Type 1 or 
Type 2 diabetes; patient group with nonhealing 
lower limb ulcers unresponsive to standard 
wound care (including debridement, glycemic 
control, antibiotic therapy, and 
revascularization if necessary); relevant 
outcomes: rate of wound/ulcer healing,wound 
size reduction, rate of major amputation 
(amputation of the lower limb proximal the 
ankle), rate of minor amputation (amputation of 
the distal end of foot), safety, and quality of life. 
This meta-anlyses shown from 654 citations 
identified, 157 articles underwent full-text 
review. Data were abstracted from twelve 
publications (six RCTs and six comparative 
observational studies). Pooled analysis of the 
RCT and observational data showed that 
treatment with HBOT reduced the risk of major 
amputation by 60 percent (p = .29) and 61 
percent (p = .003) compared with standard 
wound care, respectively. The RCT data 
revealed that the relative risk of having an 
unhealed wound following HBOT was 0.54 (p 
= .10) and 0.24 (p <.0001) based on 
observational data. 
 Liu, et al., (2013), also did a systematic 
review and meta-analysis from thirteen trials (a 
total of 624 patients), including 7 prospective 
randomized trials, performed between January 
1, 1996, and April 20, 2012. Pooling analysis 
revealed that, adjunctive treatment with HBOT 
resulted in a significantly higher proportion of 
healed diabetic ulcers compared with treatment 
without HBO (relative risk, 2, 33; 95% CI, 1, 
51-3, 60). From blood circulation evaluation, 
HBOT also has a significan influence on 
diabetic patients with chronic non-healing foot 
ulcers. Londahl, et al. (2010) have shown that 
in the HBOT group TcPO2 were significantly 
lower for patients whose ulcer did not heal as 
compared with those whose ulcers healed. A 
significantly increased healing frequency was 
seen with increasing TcPO2 levels in the HBOT 
group (TcPO2/healing rate: <25 mmHg/0%; 
26–50 mmHg/50%; 51–75 mmHg/73%; and 
>75 mmHg/100%). 
In elderly diabetic patient, HBOT also 
has a role to heal foot ulcer. Grimaldi, et al., 
(2013) did observational study in 7 elderly with 
mean 66 years that got two stages of the 
treatment (between January and September 
2012), at the first stage the patients were treated 
with medical therapy, surgical debridement, 
exudate management and stimulation of 
granulation and epithelialization with advanced 
wound dressings, wound swabs and orthotics,  
in a second time were matched HBOT cycles. 
The follow-up was done by clinical and 
biochemical controls with particular attention 
to the glycemic profile and obtaining optimal 
levels of glycated hemoglobin, and taking 
cilostazol tablets 100 mg, possibly associated 
with antiplatelets (cardioaspirin, clopidogrel). 
They observed that 3  patients needed just two 
weeks of HBOT, while other 2 ones needed 4 
weeks to get the necessary surgical healing of 
the lesions, seen as complete epithelial 
regeneration, also evaluated with ultrasound of 
the foot to highlight the possible persistence of 
outbreaks internal abscess. Other 2 patients 
required 6 weeks of HBOT. There were no 
adverse events. After almost a year, no one has 
suffered amputation of the limb and in only one 
case it was observed ulcer recurrence, in 
January 2013 , treated with the same method, 
and healed in 6 weeks of treatment. 
Despite previous studies, a longitudinal 
observational cohort study by Margalis et al., 
(2013) that the data taken from the National 
Healing Corporation (NHC) between 
November 2005 and May 2011, shown from 
6.259 individuals with diabetes, adequate lower 
limb arterial perfusion, and foot ulcer extending 
through the dermis, representing 767.060 
person-days of wound care. In the score-
adjusted models, individuals receiving HBO 
were less likely to have healing of their foot 
ulcer (hazard ratio 0, 68 [95% CI 0, 63-0, 73]) 
and more likely to have an amputation (2, 37 [1, 
84-3, 04]). Their additional analyses, including 
the use of an instrumental variable, were 
conducted to assess the robustness of our results 
to unmeasured confounding. HBO was not 
found to improve the likelihood that a wound 
might heal foot ulcer. 
HBOT and Prevention Risk to Amputation 
A meta-analyses from Rielli, et al (2013) 
of the 654 citations identified, 157 articles 
underwent full-text review. Data were 
abstracted from twelve publications (six RCTs 
and six comparative observational studies). 
Pooled analysis of the RCT and observational 
data showed that treatment with HBOT reduced 
the risk of major amputation by 60 percent (p= 
0, 29) and 61 percent (p = 0, 003) compared 
with standard wound care, respectively.  
The analysis from Liu, et al., (2013) 
also revealed that treatment with HBO was 
associated with a significant reduction in the 
risk of major amputations (relative risk, 0, 29; 
95% CI, 0, 19–0, 44); however, the rate of 
minor amputations was not affected. Adverse 
events associated with HBO treatment were 
rare and reversible and not more frequent than 
those occurring without HBO treatment. A 
review of 6 studies prepared by Roeckl-
Wiedmann et al., (2005) demonstrated that 
additional application of HBOT reduced the 
risk of amputation in 118 patients (Waniczek, 
2013).  
However, Margalis, et al., (2013) also 
shown their analyses from longitudinal 
observational that individuals receiving HBOT 
were more likely to have an amputation (2, 37 
[1, 84-3, 04]). Their additional analyses, 
including the use of an instrumental variable, 
HBOT was not found to decrease the likelihood 
of amputation in any these anlyses.   
HBOT and Cost Efficiency 
Lipsky & Berendt (2010), said that 
HBOT is avalaible in only a minority of 
communities because it is very expensive. In 
USA a full course of treatment typically cost 
$50.000 (medicare) to $200.000 (private pay). 
But limited economic analyses using the lawed 
primary clinical data have suggested, however, 
that HBOT is potentially cost effective or even 
cost saving (Lipsky & Berendt, 2010). 
In Canada, Chuck et al., (2008) 
developed a decision model comparing 
adjunctive HBOT with standard care alone. The 
population was a 65-year-old cohort with 
diabetic foot ulcer (DFU). The time horizon 
was 12 years taken from a Ministry of Health 
perspective. The health states were a healed 
wound with or without a minor lower extremity 
amputations (LEA), an unhealed wound with 
no related surgery, and a major LEA. Efficacy 
data were based on outcomes reported in 
studies included in a literature review. Cost and 
capacity needs for treating DFU patients in 
Canada were estimated using prevalence data 
from the literature, and cost and utilization data 
from government records. Their result shown 
that the 12-year cost for patients receiving 
HBOT was CND $40, 695 compared with CND 
$49,786 for standard care alone. Estimated cost 
to treat all prevalent DFU cases in Canada was 
CND$14, 4–19, 7 million/year over 4 years. If 
seven-person HBOT chambers were used, a 
further nineteen to thirty-five machines would 
be required nationally. 
 
DISCUSSION 
After reviewing  the literatures about the 
effectiveness of HBO therapy on wound 
healing in patients with DFU and effectiveness 
of HBO therapy on the prevention of the risk of 
amputation in patients with DFU, In a meta 
analasys conducted by Rui Liu, et al (2013) 
showed  that an adjunctive therapy of HBO  
increases the likelihood of  healing of diabetic 
foot ulcers and reduce the incidence of major 
amputations. Besides that, adverse effects on 
HBO therapy is rare and  acceptable. This study 
supports the concept that an adjunctive 
treatment with HBO therapy promotes healing 
of foot ulcers in diabetic patients, especially 
patients with diabetes mellitus with chronic 
ulcers and with regard to the value of arterial 
blood pressure in the lower extremities where 
patients with arterial blood pressure in the legs 
as low as 5 mmHg in the group receiving 
therapy HBO shows the results wounds that do 
not heal. 
Based on  research conducted by Daria, 
et al (2013) RCT study and comparative  
observational study suggested  that the 
application of HBO therapy reduces major and 
minor amputation  rate, and increase the rate of 
wound healing in non-healing diabetic ulcers of 
the lower extremities. There is a statistically 
significant reduction in amputations and 
improvement in wound healing when data from 
observational comparative studies were 
combined  but not significant when data RCT 
studies were combined for their methodological 
weaknesses in the research associated with the 
process of blinding. Based on research 
conducted  by Londahl (2010), about the HBOT 
on amputations and the patient in HBOT and 
placebo group, the risk of amputation is lower 
in the HBOT group than in the placebo group, 
but it may happen to both group because 
amputation is depend on patient foot arterial 
blood pressure and general condition, which 
arterial blood pressure ≤ 15 mmHg affected 
lower limb.  
These results are consistent with the 
theory of the benefits of HBO therapy one of 
which is for wound healing. In the wounds are 
part of the body that experienced edema and 
infection. This edema section are free radicals 
in large numbers. edema area is experiencing 
hypo-oxygen conditions due to hypoperfusion. 
Increased fibroblast that will promote 
vasodilation in the edema region, then the 
condition of the injured area becomes 
hipervaskular, hypercellular and hyperoxia. 
With high pressure oxygen exposure increased 
IFN-γ, i-NOS and VEGF. IFN-γ causes CD4 T-
cells (TH-1) increased the effect on β-cell 
resulting in increased Ig-G. With increasing Ig-
G, the effect of phagocytic leukocytes will also 
increase. Thereby granting the HBO on cuts 
will serve to lower the infection and edema 
(mahdi, 2009  cited by Yoland, 2015). The 
mechanism of HBO with fibroblast 
proliferation and collagen synthesis of 
Angiotensin. The next effect is as antimicrobial 
either directly or indirectly. wounds that do not 
close including diabetic foot ulcers. HBO 
therapy is used in conjunction with debridimen 
wounds, wound closure and blood sugar control 
and administration of appropriate antibiotics 
(Adityo, 2015)  it was supported  by the 
statement in the article that was written by 
Catherine, (2002) that  HBO  is an adjunctive 
therapy and will never replace a major wound 
care. American Diabetes Association  
recommends hyperbaric oxygen therapy as an 
adjunctive therapy for severe  injury or threaten 
the limbs, unresponsive to other treatments, 
especially if ischemia that can not be corrected 
with vascular surgery. the results  showed  the 
average level of recovery after HBO therapy 
was 89%, compared with 61% after 
conventional treatments.  
But we found one an article by 
Margalis et al., (2013), after longitudinal 
observation for about 6 years at National 
Healing Corporation (NHC) and  the study was 
review and approved by the Institutional 
Review Board of the University of 
Pennsylvania, their result is different from other 
tudies, in the propensity score-adjusted models 
individuals receiving HBO were less likely to 
have healing of their foot ulcer and more likely 
to have an amputation. HBO was  not found to 
improve the likelihood that a wound might heal 
or to decrease the ikelihood of amputation in 
any of their analyses. This founding is 
significant enough because they used PS 
approaches to compensate for the lack of 
randomized treatment assignment as well an 
istrumental variable analyses  to confirm their 
finding, also the subjects were more than 100 
were eligible patients and in longitudinal time.  
CONCLUSION 
HBO therapy is an an  adjunctive therapy 
in patients with DFU  that  is unresponsive to 
other treatments, especially if ischemia that can 
not be corrected with vascular surgery, but now 
days it needs to be reevaluated. HBO therapy 
will provide an effect on the condition of good 
extremity vascular status so it can minimize the 
likelihood of major or minor amputation but 
can not prevent absolutely for amputation. 
Although  HBOT is expensive but it is 
potentially cost effective or even cost saving. 
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